Relmada Therapeutics, Inc.
RLMD
$7.49
$0.040.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.57% | -32.80% | -20.17% | -25.89% | -22.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.55% | -36.88% | -22.78% | -19.70% | -19.10% |
| Operating Income | 29.55% | 36.88% | 22.78% | 19.70% | 19.10% |
| Income Before Tax | 28.25% | 35.05% | 21.85% | 19.71% | 19.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.25% | 35.05% | 21.85% | 19.71% | 19.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.25% | 35.05% | 21.85% | 19.71% | 19.04% |
| EBIT | 29.55% | 36.88% | 22.78% | 19.70% | 19.10% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 43.28% | 37.37% | 23.17% | 20.04% | 19.22% |
| Normalized Basic EPS | 43.21% | 38.10% | 22.63% | 18.86% | 18.63% |
| EPS Diluted | 43.28% | 37.37% | 23.17% | 20.04% | 19.22% |
| Normalized Diluted EPS | 43.21% | 38.10% | 22.63% | 18.86% | 18.63% |
| Average Basic Shares Outstanding | 30.86% | 5.30% | 2.86% | 0.42% | 0.21% |
| Average Diluted Shares Outstanding | 30.86% | 5.30% | 2.86% | 0.42% | 0.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |